<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>The lysosome–cathepsin axis in pancreatic cancer</dc:title><dc:creator>Mazej Jeram,	Nika	(Avtor)
	</dc:creator><dc:creator>Senjor,	Emanuela	(Avtor)
	</dc:creator><dc:creator>Kos,	Janko	(Avtor)
	</dc:creator><dc:creator>Perišić,	Milica	(Avtor)
	</dc:creator><dc:subject>tumor microenvironment</dc:subject><dc:subject>autophagy</dc:subject><dc:subject>therapeutic resistance</dc:subject><dc:subject>immune evasion</dc:subject><dc:subject>extracellular matrix remodelling</dc:subject><dc:subject>cytotoxic cells</dc:subject><dc:subject>antigen presentation</dc:subject><dc:subject>lysosome</dc:subject><dc:description>Pancreatic cancer remains one of the most lethal malignancies worldwide, with pancreatic ductal adenocarcinoma accounting for the vast majority of cases and characterized by extensive desmoplasia, immune exclusion, and resistance to systemic therapies. Increasing evidence implicates lysosomal cathepsins as important regulators of these defining features of pancreatic tumor biology. Cathepsin-dependent proteolysis and lysosome-associated signaling pathways contribute to extracellular matrix remodeling, regulate immune cell trafficking, and influence antigen processing and presentation. Beyond their classical degradative functions, cathepsins participate in stress-adaptive cellular programs linked to autophagy, metabolic regulation, and proteostasis, supporting tumor cell survival under hypoxic, nutrient-limited, and therapy-induced stress conditions. Within the tumor microenvironment, dysregulated cathepsin activity promotes immune evasion by reshaping cytokine networks, impairing effective antigen presentation, and reinforcing physical and functional barriers to cytotoxic T-cell infiltration. Collectively, these mechanisms position the lysosome–cathepsin system as a central regulator of proteolytic remodeling, immune exclusion, and adaptive therapy resistance in pancreatic cancer, highlighting its potential relevance for emerging combinatorial therapeutic strategies.</dc:description><dc:publisher>MDPI</dc:publisher><dc:date>2026</dc:date><dc:date>2026-06-05 09:39:40</dc:date><dc:type>Neznano</dc:type><dc:identifier>29780</dc:identifier><dc:identifier>UDK: 577</dc:identifier><dc:identifier>ISSN pri članku: 2218-273X</dc:identifier><dc:identifier>DOI: 10.3390/biom16060824</dc:identifier><dc:identifier>COBISS_ID: 280443139</dc:identifier><dc:source>Švica</dc:source><dc:language>sl</dc:language><dc:rights>© 2026 by the authors.</dc:rights></metadata>
